Shopping Cart
- Remove All
- Your shopping cart is currently empty
HX103, an epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI)-based fluorogenic probe, exhibits selective inhibition towards various EGFR mutations, including EGFR 19 del, EGFR L858R, EGFR wild type, and EGFR T790M, with respective IC50 values of 1.3, 1.5, 4.0, and 977 nM. It is utilized for quantifying active-EGFR to foresee agent sensitivity in NSCLC (non-small cell lung cancer) patients harboring EGFR-activating mutations [1].
Pack Size | Price | Availability | Quantity |
---|---|---|---|
25 mg | Inquiry | 3-6 months | |
50 mg | Inquiry | 3-6 months | |
100 mg | Inquiry | 3-6 months |
Description | HX103, an epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI)-based fluorogenic probe, exhibits selective inhibition towards various EGFR mutations, including EGFR 19 del, EGFR L858R, EGFR wild type, and EGFR T790M, with respective IC50 values of 1.3, 1.5, 4.0, and 977 nM. It is utilized for quantifying active-EGFR to foresee agent sensitivity in NSCLC (non-small cell lung cancer) patients harboring EGFR-activating mutations [1]. |
Targets&IC50 | EGFR L858R:1.5 nM, EGFR T790M:977 nM, EGFR WT:4.0 nM, EGFR del19:1.3 nM |
Molecular Weight | 602.04 |
Formula | C26H25ClFN7O5S |
Cas No. | 2566466-98-4 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.